A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis

INTRODUCTION
Polyunsaturated fatty acids (PUFA) can be beneficial in the management of canine atopic dermatitis (cAD). A commercial product PCSO524 containing PUFA has demonstrated anti-inflammatory effects in dogs.
Hypothesis/Objectives:
To evaluate the efficacy of PCSO-524, in combination with oclacitinib in dogs with cAD.
Animals:
Seventeen client-owned dogs with cAD.
Materials and Methods:
A randomised, double-blinded, controlled trial. All dogs were treated with oclacitinib (0.4–0.6mg/kg) twice a day for 14days, then once a day until Day (D)42. They were randomly divided into two groups: PCSO-524 (n=9) and sunflower oil (n=8). Clinical status was assessed by Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04) and pruritus Visual Analog Scale (pVAS) at baseline (D0), D14, D28 and D42. Trans epidermal water loss (TEWL) was measured at the same time points.
Results:
CADESI scores decreased significantly after treatment and there was a significant difference between the PCSO-524 and the control group at D28 (p=0.04) and D42 (p=0.03). The PCSO-524 group also demonstrated a significantly decreased pVAS on D28 and D42 (p<0.001 and p<0.001) compared to D0, while significant differences were observed in the control group at D14 and D28 (p<0.01 and p=0.04) and not at D42 (p=0.12). The mean TEWL showed a significant decrease at D28 and D42 in the PCSO-524 group, compared to the control group (p=0.002 and p<0.001).
Conclusions and Clinical Relevance:
The combination of PCSO-524 and oclacitinib may help to alleviate the rebound effect that occurs when tapering down the dosage of oclacitinib, as compared to using oclacitinib alone for the management of cAD.
KEYWORDS:
atopic dermatitis, essential fatty acids, oclacitinib, PCSO-524, rebound effect
. . . VIEW

. . . VIEW
Preliminary Study on Treatment Outcomes and Prednisolone Tapering after Marine Lipid Extract EAB-277 Supplementation in Dogs with Immune-Mediated Hemolytic Anemia
Preliminary Study on Treatment Outcomes and Prednisolone Tapering after Marine Lipid Extract EAB-277 Supplementation in Dogs with Immune-Mediated Hemolytic Anemia

 

Simple Summary: Immune-mediated hemolytic anemia (IMHA) in dogs is a common autoimmune disease which is accompanied with a high death rate and therapeutic challenges. A natural antiinflammatory nutraceutical product, EAB-277, is derived from marine lipids. Unfortunately, the effects of EAB-277 in IMHA dogs has rarely been investigated. The objective of this study is to assess the clinical effects of EAB-277 and prednisolone dose-tapering for supplemental therapy in IMHA dogs. The findings provide evidence that standard therapy combined with EAB-277 can improve hematological and blood chemistry profiles, resulting in a higher survival rate in IMHA dogs. Furthermore, EAB-277 supplementation can reduce prednisolone dosage tapering and improve the quality of life of IMHA dogs. However, a longer-term study with a larger sample size is necessary to corroborate these findings. As a result, marine EAB-277 is a promising alternative to existing medication for IMHA. Since the nutraceuticals have been utilized not only for nutrition but also as supplemental therapy for the treatment of a wide range of illnesses, such as minimizing the adverse effects of immunosuppressive therapy with steroids.

 

 

 

. . . VIEW

 

Preliminary Study on Treatment Outcomes and Prednisolone Tapering after Marine Lipid Extract EAB-277 Supplementation in Dogs with Immune-Mediated Hemolytic Anemia
Preliminary Study on Treatment Outcomes and Prednisolone Tapering after Marine Lipid Extract EAB-277 Supplementation in Dogs with Immune-Mediated Hemolytic Anemia
. . . VIEW

 

 

 

Canine tracheal collapse is a progressive disease in small breed dogs resulting from chronic inflammation of the tracheal mucosal lining. Polyunsaturated fatty acid EAB-277® is one of the nutraceuticals that can alleviate inflammation and oxidative stress. Heart rate variability (HRV) is a prognostic tool related to sympathovagal balance and oxidative stress level, which is widely used with cardiorespiratory diseases. However, the effect of EAB-277® on HRV in tracheal collapse dogs has rarely been investigated.

Introduction: Glucosamine hydrochloride and chondroitin sulfate are commonly used in dogs with OA, but evidence around efficacy is mixed. This study evaluated the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the alleviation of canine hip OA pain. This was a prospective, block-randomized, double-blinded, placebo-controlled clinical trial.

Methods: Seventy-five owned pet dogs with hip OA were assigned randomly into five treatment groups: PCSO-524, Glucosamine and chondroitin sulfate, EAB-277, carprofen, and Placebo (sunflower oil). Peak vertical force (PVF) and subjective orthopedic assessment scores (OAS) were evaluated before treatment (week 0), and at weeks 2, 4, and 6 during treatment.

Results: At week 2, the carprofen group showed a significant increase in PVF (3.14 ± 5.33; mean ± SD). After 4 weeks, the increases in PVF of the PCSO-524 (3.90 ± 3.52), EAB-277 (4.17 ± 4.94), and carprofen (3.08 ± 5.87) groups were significant, and significantly greater than placebo (0.08 ± 1.90) and glucosamine (−0.05 ± 6.34) groups. After 6 weeks, the change of PVF in the PCSO-524 (4.14 ± 4.65), EAB-277 (4.45 ± 4.23), and carprofen (4.21 ± 6.52) groups were significant and significantly higher than the placebo group (−0.33 ± 3.65). The change in PVF in the glucosamine group (1.08 ± 5.49) lay between the placebo group and the other treatment groups. The OAS did not show any significant change in any group.

Discussion: PCSO-524 and EAB-277, but not glucosamine/chondroitin, resulted in significant improvements in PVF from baseline after 4 weeks, and 6 weeks, and to a similar degree to that seen with carprofen.

 

 

 

 

 

. . . VIEW

. . . VIEW

Updated Study Topics

New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted

 

Discover More Studies
Click to see the digital library